Novavax today announced that a U.S. government delegation visited the Serum Institute of India (SII), celebrating the importance and impact of 75 years of U.S.-India bilateral partnership. Attendees included Stanley C. Erck, President and Chief Executive Officer, Novavax; Gregory M. Glenn, M.D., President of Research and Development, Novavax; U.S. Mission Chargé d'Affaires Patricia Lacina; U.S. Consul General in Mumbai Mike Hankey; Dr. Preetha Rajaraman, HHS Health Attaché; FDA Country Director Dr. Sarah McMullen; Dr. Cyrus Poonawalla, Chairman & MD, SII; and Mr. Adar Poonawalla, CEO, SII.
The event also highlighted the partnership between Novavax and SII on vaccine manufacturing, which was recognized for its contribution to increasing global access to effective and affordable COVID-19 vaccines. Novavax and SII are key partners in the manufacturing of Novavax’ vaccine, marketed by Novavax as Nuvaxovid™ and by SII as Covovax™.
“India has played a crucially important role during the devastating pandemic. As it emerges as one of the fastest growing large economies in the world, it will continue to have a powerful impact on all fronts,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “The US-India ties are even stronger than before and aligned in values and vision. Novavax and Serum Institute of India are committed to growing these partnerships to leverage our collective dedication, ingenuity, and expertise to protect the health of people everywhere.”
Trade Name in the U.S.
The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.